Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.

ABSTRACT:

Objective

To use the large dataset from the Tysabri Outreach: Unified Commitment to Health (TOUCH) program to compare progressive multifocal leukoencephalopathy (PML) risk with natalizumab extended interval dosing (EID) vs standard interval dosing (SID) in patients with multiple sclerosis (MS).

Methods

This retrospective cohort study included anti-JC virus antibody-positive patients (n = 35,521) in the TOUCH database as of June 1, 2017. The effect of EID on PML risk was evaluated with 3 planned analyses using Kaplan-Meier methods stratified by prior immunosuppressant use. Risk of PML was analyzed by Cox regression adjusted for age, sex, prior immunosuppressants, time since natalizumab initiation, and cumulative number of infusions.

Results

This study included 35,521 p

SUBMITTER: Ryerson LZ 

PROVIDER: S-EPMC7010325 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature